Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrine Function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    391 result(s) found for: Endocrine Function. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001911-31 Sponsor Protocol Number: 30032006 Start Date*: 2007-06-27
    Sponsor Name:Universitätsfrauenklinik Innsbruck
    Full Title: Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie
    Medical condition: Polycystic ovary syndrome is one of the most common endocrine disorders, affecting approximately 10% of women of reproductive age, associated with hyperandrogenaemia and menstrual dysfunction. The ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014695 Endocrine disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003027-15 Sponsor Protocol Number: EFFI2021/01 Start Date*: 2023-03-20
    Sponsor Name:ITALFARMACO S.P.A.
    Full Title: A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgest...
    Medical condition: Combined Oral Contraceptives (COC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022821-14 Sponsor Protocol Number: 2010-022821-14 Start Date*: 2010-11-11
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Cardiovascular Outcomes of Replacement with Testosterone. Role of testosterone replacement therapy in patients with heart failure.
    Medical condition: MALE HYPOGONADISM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014698 SOC
    9.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001898-78 Sponsor Protocol Number: CABOTEM Start Date*: 2020-11-12
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of combination between Cabozantinib and Temozolomide in Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib...
    Medical condition: Patient with Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib or PRRT.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028196 Multiple endocrine neoplasias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005055-23 Sponsor Protocol Number: ENDO-002/08 Start Date*: 2009-03-05
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET
    Medical condition: Primary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027180 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004854-29 Sponsor Protocol Number: S245.4.008 Start Date*: 2007-09-21
    Sponsor Name:Abbott Products GmbH
    Full Title: One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon® 25000 Minimicrospheres™ in subjects with pancreatic exocrine insufficiency after pancreatic sur...
    Medical condition: Pancreatic Exocrine Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004362-26 Sponsor Protocol Number: I3Y-MC-JPCF Start Date*: 2017-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ...
    Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Ongoing) FR (Ongoing) PT (Trial now transitioned) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-005181-30 Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 Start Date*: 2015-07-09
    Sponsor Name:ABCSG GmbH
    Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor...
    Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-001370-88 Sponsor Protocol Number: IBCSG 35-07/ BIG 1-07 Start Date*: 2007-11-06
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor...
    Medical condition: Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocri...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed) DK (Completed) GB (Completed) ES (Completed) SI (Completed) GR (Completed) AT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003553-19 Sponsor Protocol Number: IBCSG59-19/BIG18-02 Start Date*: 2019-06-25
    Sponsor Name:International Breat Cancer Study Group (IBCSG)
    Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2...
    Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002781-48 Sponsor Protocol Number: MedOPP068 Start Date*: 2019-02-08
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN H...
    Medical condition: Hormone receptor-positive/HER2-negative Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) DE (Completed) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000879-24 Sponsor Protocol Number: IJB-BC-NEORHEA-2016 Start Date*: 2017-03-23
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007030-20 Sponsor Protocol Number: N07MAN Start Date*: 2008-03-20
    Sponsor Name:NKI-AVL
    Full Title: RANDOMIZED PHASE II/III STUDY OF SECOND-LINE ENDOCRINE TREATMENT FOLLOWED BY CAPECITABINE VERSUS CAPECITABINE FOLLOWED BY ENDOCRINE TREATMENT IN PATIENTS WITH METASTATIC ER POSITIVE BREAST CANCER
    Medical condition: metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001921-31 Sponsor Protocol Number: GRACE Start Date*: 2021-10-25
    Sponsor Name:University Hospital Ghent
    Full Title: GRACE-trial: A randomized active-controlled trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy
    Medical condition: Breast cancer patients on endocrine therapy (AI or SERM) with symptoms of vulvovaginal atrophy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000617-43 Sponsor Protocol Number: CLEE011F2301 Start Date*: 2015-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2...
    Medical condition: men and postmenopausal women with HR+, HER2-negative advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) DK (Completed) NL (Completed) HU (Completed) BE (Completed) BG (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005326-29 Sponsor Protocol Number: IBCSG_41-13 Start Date*: 2013-11-11
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine r...
    Medical condition: Premenopausal patients with histologically confirmed locally advanced breast cancer and with primary tumor of ER+/PgR+ and HER2 negative or not amplified.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004324-30 Sponsor Protocol Number: MedOPP167 Start Date*: 2019-02-04
    Sponsor Name:Medica Scientia Innovation Research (MEDSIR)
    Full Title: A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progre...
    Medical condition: Luminal Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006050-25 Sponsor Protocol Number: 20060362 Start Date*: 2008-05-15
    Sponsor Name:Amgen Inc.
    Full Title: An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Me...
    Medical condition: Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA